In this online CME self-learning program:
Atypical hemolytic uremic syndrome (aHUS) is a disease in which the complement system is activated in an uncontrolled manner outside the presence of coexisting disease, resulting in platelet activation, damage to endothelial cells, and a range of clinical sequelae including: which may ultimately lead to kidney failure; systemic thrombotic microangiopathy;anemia; and thrombocytopenia.The disease may arise from any of a number of genetic mutations of the complement system or the presence of anti-complement factor H. While it is estimated to occur at an equally commonly between males and females, the disease is rare with an estimated incidence of about 2 people per million in the U.S. and seven per million in Europe.
The following healthcare professionals: hematologists, nephrologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists specializing in hematology and transplant medicine; and any other healthcare professionals with an interest in or who may clinically encounter patients with aHUS.
This activity is supported by an educational grant from Alexion.
This activity is free of charge.
Release Date: July 10, 2019 -- Expiration Date: July 10, 2021
Faculty: Ramy Hanna, MD
Pathophysiology and diagnosis, future complications [Learning objectives #1 and #2]
Treatment [Learning objectives #3 and #4]
Summary, conclusions, and best practice recap
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Ramy Hanna, MD, Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA, is a consultant for Alexion pharmaceuticals.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, CEO of ScientiaCME, has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This program is supported by an educational grant from Alexion
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.